Alvogen Imbruvica Ruling Set To Push AbbVie’s Monopoly To 2032
Icelandic Firm And Partner Natco Fail With Invalidity Challenges
Alvotech and Natco have failed to persuade a US court that certain of AbbVie’s IP shielding its Imbruvica blockbuster is invalid. In response, the originator said that it did not anticipate generic competition to its branded oral therapy for treating forms of cancer until March 2032, assuming pediatric exclusivity is granted.
